

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter G. KLIMKO

Serial No: 10/575,911

Filed: 14 April 2006

Examiner:

Group Art Unit:

FOR: SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OPTIC NERVE
AND RETINAL DAMAGE**INFORMATION DISCLOSURE STATEMENT PURSUANT
TO 37 C.F.R. 1.56, 1.97, AND 1.98**

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

A copy of the International Search Report issued in the PCT application, of which the present application is a 35 U.S.C. §371 application, is also included for the Examiner's convenience.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

16 August 2006
 Date

By: Teresa J. Schultz
 Teresa J. Schultz
 Registration No. 40,256
 (817) 551-4231

Address for Correspondence:

Alcon Research, Ltd.
 Attn: Teresa J. Schultz
 6201 S. Freeway, Mail Code TB4-8
 Fort Worth, TX 76134-2099
 Attorney Docket No.: 2509 US F

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/575,911
		Filing Date	April 14, 2006
		First Named Inventor	Peter G. KLIMKO
		Art Unit	
		Examiner Name	
Sheet	2	of	3
		Attorney Docket Number	2509 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2A	Baker et al., J. PHARMACOL. EXP. THER. 284:215-221 (1998)	
	2B	Clark, AF, "Current trends in antiglaucoma therapy," EMERGING DRUGS 4:333-353 (1999)	
	2C	David, R, "Neuroprotection of the optic nerve in glaucoma," ACTA OPHTHALMOL. SCAND. 75:364-367 (1997) [article lists as "Caprioli"]	
	2D	David, R, "Changing therapeutic paradigms in glaucoma management," EXPERT OPIN. INVEST. DRUGS 7:1063-1086 (1998)	
	2E	Doctrow et al., J. MED. CHEM. 45:4549-4558 (2002)	
	2F	Jiang et al., CHEM. RES. TOXICOL. 12:429-436 (1999)	
	2G	Jiang and Dryhurst, CHEM. RES. TOXICOL. 15:1242-1247 (2002)	
	2H	Melov et al., J. NEUROSCI., 21:8348-8353 (2001)	
	2I	PCT International Search Report for corresponding PCT application PCT/US04/39830 with May 31, 2005 mailing date	
	2J	Qi et al., OPHTHALMOL. VIS. SCI. 44(3):1088-1096 (2003)	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/575,911
				Filing Date	April 14, 2006
				First Named Inventor	Peter G. KLIMKO
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	2509 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3A	Rios et al., J. OCUL. PHARMACOL. THER. 15(6):547-556 (1999)	
	3B	Salvemini, D et al., SCIENCE 286:304-306 (1999)	
	3C	Salvemini, D et al., DRUGS FUTURE 25(10):1027-1033 (2000)	
	3D	Salvemini, D et al., J. PHARMACOL. EXP. THER. 301(2):478-487 (2002a) actually listed as "McInnis"	
	3E	Salvemini, D et al., BR. J. PHARMACOL. 136(6):905-917 (2002b) actually listed as "Masini"	
	3F	Sandbach et al., INVEST. OPHTHALMOL. VIS. SCI. 42(10):2173-2178 (2001)	
	3G	Wang et al., RES. COMMUN. MOL. PATHOL. PHARMACOL. 89:291-305 (1995)	
	3H	Wrona and Dryhurst, CHEM. RES. TOXICOL. 11:639-650 (1998)	
	3II	Wrona and Dryhurst, CHEM. RES. TOXICOL. 14:1184-1192 (2001)	
	3J		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



AUG 24 2006

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/575,911
Filing Date	14 April 2006
First Named Inventor	Peter G. KLIMKO
Art Unit	
Examiner Name	
Attorney Docket Number	2509 US F

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 24 References and Return Card.
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Teresa J. Schultz		
Date	16 August 2006	Reg. No.	40,526


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Barbara McKenzie	Date	16 August 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

off

3

Attorney Docket Number 2509 US F

Application Number	10/575,911
Filing Date	April 14, 2006
First Named Inventor	Peter G. KLIMKO
Art Unit	
Examiner Name	
Attorney Docket Number	2509 US F

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
1I	WO 98/58636 A1	/	12/30/1998	G. D. Searle		
1J	WO 00/07584 A2 and A3	-	02/17/2000	Wisconsin Alumni Res.		
1K	WO 00/19993 A2 and A3	-	04/13/2000	Brownlee		
1L	WO 00/72893 A2 and A3	-	12/07/2000	Monsanto Co.		
1M	WO 2005/060974 A1	.	07/07/2005	Alcon, Inc.		

Examiner Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT S

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.